monofluorophosphate

Small moleculeapproved

Approved

Aug 6, 1986

Monofluorophosphate (MFP) is an anion, which is a phosphate group with one oxygen atom substituted with a fluorine atom. Sodium Monofluorophosphate is intended to be used by both petitioners in food supplements as a source of fluoride in the forms of multi-vitamin, multi-mineral supplements, solid tablets or tablets dispersible in liquid. The toxic effects of Monofluorophosphate are attributable to the fluoride ion released by the in vivo hydrolysis of the parent compound. The Monofluorophosphate ion appears to play no role. The acute toxicity of Monofluorophosphate is somewhat less than that of NaF, due to the lesser availability of fluoride in the short term from Monofluorophosphate. In the long term, Monofluorophosphate produces virtually the same picture of renal effects and skeletal storage of fluoride as does NaF. Sodium Monofluorophosphate dissociates into sodium and Monofluorophosphate ions in the intestinal tract, the latter being absorbed mainly in the upper small intestine. — NCATS

Clinical trial activity

50 trials · 20 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Nov 1, 1999 (NCT00138827)

Timeline

1980s

Aug 6, 1986
Chesebrough-Ponds — Earliest FDA Approval
Aug 6, 1986
Chesebrough-Ponds — NDA Organization

2000s

Jan 1, 2008
Earliest Phase 3 Sponsor(trial)
Jan 1, 2009
Earliest Phase 2 Sponsor(trial)

2020s

Jan 1, 2025
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Streptococcus mutansANTAGONIST
Streptococcus mutans antagonist

Approval history

approvedAug 6, 1986

Chemistry & pharmacology

Loading structure…

SMILES

[O-]P([O-])(F)=O

Mol. weight: 97.9704 g/mol
Chirality: Achiral Molecule
Inorganic: Yes
Polymer: No
Delivery: Topical
Availability: Discontinued

Oral

Parenteral

Topical

Yes

Sources

Also known as

ammonium monofluorophosphate
biotene
calcium fluorophosphate
calcium monofluorophosphate
disodium fluorophosphate
disodium monofluorophosphate
extra-strength aim
extra-strength aim
extra-strength aim
fluorophosphate
fluorophosphate, barium salt
fluorophosphate, calcium salt
fluorophosphate, diammonium salt
fluorophosphate, disodium salt
fluorophosphate hydrate, calcium salt
fluorophosphate, monoammonium salt
fluorophosphate, potassium salt
fluorophosphate, sodium salt
fluorophosphate, tin salt
fluorophosphate, vanadium salt
monofluorophosphate
monofluorophosphate
monofluorophosphate
mono-tridin
mono-tridin
mono-tridin
na-mfp
sodium fluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monofluorophosphate
sodium monoflurophosphate
sodium phosphorofluoridate

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06962956	Phase 1	Apr 30, 2025	Procter and Gamble, Salus Research
NCT06140784	N/A	Sep 2, 2023	Procter and Gamble
NCT06140758	N/A	Jul 31, 2023	Procter and Gamble
NCT05596149	N/A	Nov 1, 2022	University of Split, University of Zagreb
NCT06197555	N/A	May 1, 2022	Altinbas University
NCT06659471	N/A	Mar 7, 2022	Procter and Gamble
NCT05916521	N/A	Nov 15, 2021	Procter and Gamble
NCT06140771	N/A	Oct 20, 2021	Procter and Gamble
NCT04966507	Phase 2	Aug 31, 2021	National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles
NCT05916508	N/A	Oct 19, 2020	Procter and Gamble
NCT04537962	N/A	Jun 11, 2020	Albert Einstein Israelite Hospital, Colgate Palmolive, University of Sao Paulo
NCT03965039	N/A	Jul 8, 2019	Procter and Gamble
NCT03936569	Phase 4	Oct 29, 2018	Procter and Gamble
NCT03936556	Phase 4	Feb 25, 2018	Procter and Gamble
NCT07223073	Phase 3	Dec 21, 2017	Colgate Palmolive, Mahidol University
NCT03310268	N/A	Nov 18, 2017	GlaxoSmithKline
NCT02937636	N/A	Sep 19, 2017	GlaxoSmithKline
NCT02522936	Phase 4	Aug 1, 2017	University of Southern California
NCT07223060	Phase 2/Phase 3 (Phase 3)	May 17, 2017	Colgate Palmolive, Mahidol University
NCT02924350	N/A	Nov 7, 2016	GlaxoSmithKline

Showing 20 of 50 trials

Page 1 / 3

Organizations

Research & Development (20)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
GlaxoSmithKline	For profit	25	25	4	2008
Procter and Gamble	For profit	10	10	3	2018
Colgate Palmolive	For profit	6	5	3	2007
Mahidol University	Academic/Hospital	2	0	1	2017
Albert Einstein Israelite Hospital	Academic/Hospital	1	1	1	2020
Altinbas University	Academic/Hospital	1	1	1	2022
BioSci Research	For profit	1	0	1	2012
Glo Science, Inc.	For profit	1	1	1	2015
Medical College of Wisconsin	Academic/Hospital	1	1	1	2016
National Institute of Allergy and Infectious Diseases (NIAID)	Government	1	0	1	2021
Salus Research	For profit	1	0	1	2025
The Forsyth Institute	Academic/Hospital	1	0	1	2015
University of California, Los Angeles	Academic/Hospital	1	1	1	2021
University of Chile	Academic/Hospital	1	1	1	2015
University of Leeds	Academic/Hospital	1	1	1	2016
University of New South Wales	Academic/Hospital	1	1	1	1999
University of Sao Paulo	Academic/Hospital	1	0	1	2020
University of Southern California	Academic/Hospital	1	1	1	2017
University of Split	Academic/Hospital	1	0	1	2022
University of Zagreb	Academic/Hospital	1	1	1	2022

20 organizations

Page 1 / 1

Marketing (1)

Organization	Org type	Relationship	Date
Chesebrough-Ponds	For profit	NDA	Aug 6, 1986